Dalfopristin

Dalfopristin
Clinical data
AHFS/Drugs.com	International Drug Names
MedlinePlus	a603007
ATC code	none;
Legal status
Legal status	US: ℞-only;
Pharmacokinetic data
Elimination half-life	1 hour
Identifiers
	IUPAC name (3R,4R,5E,10E,12E,14S,26R,26aS)-26-[[2-(diethylamino)ethyl]sulfonyl]-8,9,14,15,24,25,26,26a- octahydro-14-hydroxy-3-isopropyl-4,12-dimethyl-3H-21,18-nitrilo-1H,22H-pyrrolo[2,1-c] [1,8,4,19]-dioxadiazacyclotetracosine-1,7,16,22(4H,17H)-tetrone;
CAS Number	112362-50-2 ;
PubChem CID	6435782;
DrugBank	DB01764 ;
ChemSpider	16736919 ;
UNII	R9M4FJE48E;
KEGG	D00853 ;
ChEBI	CHEBI:4309;
ChEMBL	ChEMBL1200937 ;
CompTox Dashboard (EPA)	DTXSID10869549 ;
Chemical and physical data
Formula	C34H50N4O9S
Molar mass	690.85 g·mol−1
3D model (JSmol)	Interactive image;
	SMILES CCN(CC)CCS(=O)(=O)[C@@H]1CCN2[C@H]1C(=O)O[C@@H]([C@@H](/C=C/C(=O)NC/C=C/C(=C/[C@H](CC(=O)CC3=NC(=CO3)C2=O)O)/C)C)C(C)C;
	InChI InChI=1S/C34H50N4O9S/c1-7-37(8-2)16-17-48(44,45)28-13-15-38-31(28)34(43)47-32(22(3)4)24(6)11-12-29(41)35-14-9-10-23(5)18-25(39)19-26(40)20-30-36-27(21-46-30)33(38)42/h9-12,18,21-22,24-25,28,31-32,39H,7-8,13-17,19-20H2,1-6H3,(H,35,41)/b10-9+,12-11+,23-18+/t24-,25-,28-,31-,32-/m1/s1 ; Key:SUYRLXYYZQTJHF-VMBLUXKRSA-N ;
	(what is this?) (verify)

Dalfopristin is a semi-synthetic streptogramin antibiotic analogue of ostreogyrcin A (virginiamycin M, pristinamycin IIA, streptogramin A).^[1] The combination quinupristin/dalfopristin (marketed under the trade name Synercid) was brought to the market by Rhone-Poulenc Rorer Pharmaceuticals in 1999.^[2] Synercid (weight-to-weight ratio of 30% quinupristin to 70% dalfopristin) is used to treat infections by staphylococci and by vancomycin-resistant Enterococcus faecium.^[3]

^ "Dalfopristin (as mesylate) (CAS 112362-50-2)". Santa Cruz Biotechnology, Inc.
^ "Synercid (Quinupristin/Dalfopristin) I.V." Drug Approval Package. U.S. Food and Drug Administration. Archived from the original on February 8, 2013.
^ Allington DR, Rivey MP (January 2001). "Quinupristin/dalfopristin: a therapeutic review". Clinical Therapeutics. 23 (1): 24–44. doi:10.1016/S0149-2918(01)80028-X. PMID 11219478.